Advanced Cervical Cancer Clinical Trial
Official title:
Phase 1 Trail to Observe Safety and Efficacy of Metronomic Capecitabine Plus PD-L1 Antibody Camrelizumab as Third-line Regimen to Treat HER2 Negative Advanced Gastric Cancer Patients
This is a single center phase 1 trail to observe safety and efficacy of metronomic capecitabine plus PD-L1 antibody camrelizumab as third-line regimen to treat HER2 negative advanced gastric cancer patients. This study is one of the cohorts of a multi-cohort trial called Combination of Metronomic capecitabine with Camrelizumab for treatment of refractory solid tumor (McCrest) trial.
HER2 negative advanced gastric cancer patients who have disease progression after two standard regimens will be treated by metronomic capecitabine plus camrelizumab. Metronomic capecitabine will be given as fixed dose (500mg bid) orally. Camrelizumab will be given two-weekly (200mg once) intravenously. This regimen will be administered until progression of disease, intolerable toxicity or withdraw of consent. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01088347 -
Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05068921 -
A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy
|
Phase 1 | |
| Completed |
NCT04590599 -
A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy
|
Phase 2 | |
| Terminated |
NCT02853604 -
Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer
|
Phase 3 | |
| Recruiting |
NCT04731038 -
Combination Therapy for First Line Treatment of Advanced Cervical Cancer
|
Phase 1 | |
| Completed |
NCT02888717 -
Molecular Biology Analysis for Para-aortic Nodes in the Ultra-staging of Advanced Cervical Cancers
|
N/A |